• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全唾液和腺泡唾液作为阿尔茨海默病诊断生物标志物的研究。

Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer's Disease Diagnosis.

作者信息

Cui Yangyang, Zhang Hankun, Zhu Jia, Liao Zhenhua, Wang Song, Liu Weiqiang

机构信息

Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.

Department of Mechanical Engineering, Tsinghua University, Beijing 100084, China.

出版信息

Brain Sci. 2022 May 3;12(5):595. doi: 10.3390/brainsci12050595.

DOI:10.3390/brainsci12050595
PMID:35624982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9139762/
Abstract

Salivary Aβ40, Aβ42, t-tau, and -tau 181 are commonly employed in Alzheimer's disease (AD) investigations. However, the collection method of these biomarkers can affect their levels. To assess the impact of saliva collection methods on biomarkers in this study, 15 healthy people were employed in the morning with six saliva collection methods. The chosen methods were then applied in 30 AD patients and 30 non-AD controls. The levels of salivary biomarkers were calculated by a specific enzyme-linked immunosorbent assay. The receiver operating characteristic was utilized to assess salivary biomarkers in AD patients. The results demonstrated that the highest levels of salivary Aβ40, Aβ42, t-tau, and -tau were in different saliva collection methods. The correlations between different saliva biomarkers in the same collection method were different. Salivary Aβ40, Aβ42, t-tau, and -tau had no significant association. Salivary Aβ42 was higher in AD than in non-AD controls. However, -tau/t-tau and Aβ42/Aβ40 had some relevance. The area under the curve for four biomarkers combined in AD diagnosis was 92.11%. An alternate saliva collection method (e.g., USS in Aβ40, UPS in Aβ42, t-tau, SSS in -tau 181) was demonstrated in this study. Moreover, combining numerous biomarkers improves AD diagnosis.

摘要

唾液中的β淀粉样蛋白40(Aβ40)、β淀粉样蛋白42(Aβ42)、总tau蛋白(t-tau)和磷酸化tau蛋白181(p-tau 181)常用于阿尔茨海默病(AD)的研究。然而,这些生物标志物的采集方法会影响其水平。为了评估本研究中唾液采集方法对生物标志物的影响,招募了15名健康人在早晨采用六种唾液采集方法进行采集。然后将所选方法应用于30例AD患者和30例非AD对照。通过特定的酶联免疫吸附测定法计算唾液生物标志物的水平。利用受试者工作特征曲线评估AD患者的唾液生物标志物。结果表明,唾液Aβ40、Aβ42、t-tau和p-tau在不同的唾液采集方法中水平最高。同一采集方法中不同唾液生物标志物之间的相关性不同。唾液Aβ40、Aβ42、t-tau和p-tau之间无显著关联。AD患者的唾液Aβ42高于非AD对照。然而,p-tau/t-tau和Aβ42/Aβ40有一定相关性。四种生物标志物联合用于AD诊断时的曲线下面积为92.11%。本研究展示了一种替代的唾液采集方法(例如,Aβ40采用超声刺激唾液采集法(USS),Aβ42、t-tau采用非刺激唾液采集法(UPS),p-tau 181采用静态唾液采集法(SSS))。此外,联合多种生物标志物可改善AD诊断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f17d/9139762/cf54de05255b/brainsci-12-00595-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f17d/9139762/31a6ae51d29b/brainsci-12-00595-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f17d/9139762/b3181949b691/brainsci-12-00595-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f17d/9139762/6bc34bf2e7c6/brainsci-12-00595-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f17d/9139762/cf54de05255b/brainsci-12-00595-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f17d/9139762/31a6ae51d29b/brainsci-12-00595-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f17d/9139762/b3181949b691/brainsci-12-00595-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f17d/9139762/6bc34bf2e7c6/brainsci-12-00595-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f17d/9139762/cf54de05255b/brainsci-12-00595-g004.jpg

相似文献

1
Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer's Disease Diagnosis.全唾液和腺泡唾液作为阿尔茨海默病诊断生物标志物的研究。
Brain Sci. 2022 May 3;12(5):595. doi: 10.3390/brainsci12050595.
2
Aβ42 as a Biomarker of Alzheimer's Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid?β淀粉样蛋白42作为阿尔茨海默病的生物标志物:唾液能否成为脑脊液的可行替代物?
Brain Sci. 2022 Dec 17;12(12):1729. doi: 10.3390/brainsci12121729.
3
CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer's Disease and Frontotemporal Dementias.阿尔茨海默病和额颞叶痴呆中的脑脊液β淀粉样蛋白42(Aβ42)及Aβ42/Aβ40比值
Diagnostics (Basel). 2023 Feb 19;13(4):783. doi: 10.3390/diagnostics13040783.
4
Correlation Between Brain Structure Atrophy and Plasma Amyloid-β and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnestic Mild Cognitive Impairment Explored by Surface-Based Morphometry.基于表面形态测量法探索阿尔茨海默病和遗忘型轻度认知障碍患者脑结构萎缩与血浆淀粉样β蛋白及磷酸化tau蛋白之间的相关性
Front Aging Neurosci. 2022 Apr 25;14:816043. doi: 10.3389/fnagi.2022.816043. eCollection 2022.
5
Alzheimer's Disease CSF Biomarker Profiles in Idiopathic Normal Pressure Hydrocephalus.特发性正常压力脑积水患者的阿尔茨海默病脑脊液生物标志物特征
J Pers Med. 2022 Jun 6;12(6):935. doi: 10.3390/jpm12060935.
6
Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.中国个体中可能患有阿尔茨海默病痴呆症的血浆β-淀粉样蛋白、tau蛋白、神经退行性变生物标志物及炎症因子
Front Aging Neurosci. 2022 Aug 18;14:963845. doi: 10.3389/fnagi.2022.963845. eCollection 2022.
7
Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.脑脊液生物标志物(磷酸化tau181、总tau、Aβ42 和 Aβ40)在阿尔茨海默病和路易体痴呆前驱期的诊断价值。
J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731.
8
Evaluation of core Biomarkers of Alzheimer's disease in saliva and plasma measured by chemiluminescent enzyme immunoassays on a fully automated platform.基于全自动平台的化学发光酶免疫分析检测唾液和血浆中阿尔茨海默病核心生物标志物的评估。
Sci Rep. 2024 Jul 12;14(1):16084. doi: 10.1038/s41598-024-66923-z.
9
Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's Disease.脑脊液Aβ40可改善Aβ42浓度对阿尔茨海默病诊断的解读。
Front Neurol. 2015 Nov 27;6:247. doi: 10.3389/fneur.2015.00247. eCollection 2015.
10
Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer's disease.星形胶质细胞反应性与阿尔茨海默病中的 tau 缠结负荷和皮质变薄有关。
Mol Neurodegener. 2024 Jul 30;19(1):58. doi: 10.1186/s13024-024-00750-8.

引用本文的文献

1
AuNP/Magnetic Bead-Enhanced Electrochemical Sensor Toward Dual Saliva Alzheimer's Biomarkers Detection.用于检测唾液中两种阿尔茨海默病生物标志物的金纳米颗粒/磁珠增强型电化学传感器
Sensors (Basel). 2025 Jun 30;25(13):4088. doi: 10.3390/s25134088.
2
Salivary levels of amyloid beta reflect brain amyloid beta burden in cognitively-normal older adults.认知功能正常的老年人唾液中β-淀粉样蛋白水平反映脑内β-淀粉样蛋白负荷。
J Prev Alzheimers Dis. 2025 Jun 9:100216. doi: 10.1016/j.tjpad.2025.100216.
3
Elevated levels of salivary interleukin-34 in patients suffering from Alzheimer's disease.

本文引用的文献

1
Correlations of Salivary and Blood Glucose Levels among Six Saliva Collection Methods.六种唾液采集方法与血糖水平的相关性研究。
Int J Environ Res Public Health. 2022 Mar 30;19(7):4122. doi: 10.3390/ijerph19074122.
2
Neurobiological advances of learned fear in humans.人类习得性恐惧的神经生物学进展。
Adv Clin Exp Med. 2022 Mar;31(3):217-221. doi: 10.17219/acem/146756.
3
Does the human ventromedial prefrontal cortex support fear learning, fear extinction or both? A commentary on subregional contributions.人类腹内侧前额叶皮层支持恐惧学习、恐惧消退还是两者皆支持?关于亚区域贡献的评论
阿尔茨海默病患者唾液中白细胞介素-34水平升高。
Clin Oral Investig. 2025 May 20;29(6):303. doi: 10.1007/s00784-025-06376-4.
4
Prospecting salivary tau as a diagnostic for Alzheimer's type dementia.探索唾液tau蛋白作为阿尔茨海默病型痴呆的诊断标志物。
Dement Neuropsychol. 2025 Apr 28;19:e20240253. doi: 10.1590/1980-5764-DN-2024-0253. eCollection 2025.
5
An Update of Salivary Biomarkers for the Diagnosis of Alzheimer's Disease.用于阿尔茨海默病诊断的唾液生物标志物最新进展
Int J Mol Sci. 2025 Feb 26;26(5):2059. doi: 10.3390/ijms26052059.
6
Detection of Aβ40 in cerebrospinal fluid and plasma of Alzheimer's disease patients using photoelectrochemical biosensors.使用光电化学生物传感器检测阿尔茨海默病患者脑脊液和血浆中的Aβ40
Mikrochim Acta. 2024 Dec 4;192(1):5. doi: 10.1007/s00604-024-06816-0.
7
Salivary biomarkers: The early diagnosis of Alzheimer's disease.唾液生物标志物:阿尔茨海默病的早期诊断
Aging Med (Milton). 2024 Feb 20;7(2):202-213. doi: 10.1002/agm2.12282. eCollection 2024 Apr.
8
Salivary Biomarkers for Alzheimer's Disease: A Systematic Review with Meta-Analysis.用于阿尔茨海默病的唾液生物标志物:系统评价与荟萃分析。
Int J Mol Sci. 2024 Jan 18;25(2):1168. doi: 10.3390/ijms25021168.
9
Neurotoxic stimulation alters prosaposin levels in the salivary systems of rats.神经毒性刺激改变了大鼠唾液系统中的前蛋白水平。
Cell Tissue Res. 2024 Feb;395(2):159-169. doi: 10.1007/s00441-023-03847-6. Epub 2023 Dec 12.
10
Using gamma-band transcranial alternating current stimulation (tACS) to improve sleep quality and cognition in patients with mild neurocognitive disorders due to Alzheimer's disease: A study protocol for a randomized controlled trial.采用伽马波段经颅交流电刺激(tACS)改善阿尔茨海默病所致轻度神经认知障碍患者的睡眠质量和认知功能:一项随机对照试验研究方案。
PLoS One. 2023 Aug 4;18(8):e0289591. doi: 10.1371/journal.pone.0289591. eCollection 2023.
Mol Psychiatry. 2022 Feb;27(2):784-786. doi: 10.1038/s41380-021-01326-4. Epub 2021 Oct 20.
4
Brain-Derived Exosomal Proteins as Effective Biomarkers for Alzheimer's Disease: A Systematic Review and Meta-Analysis.脑源性外泌体蛋白作为阿尔茨海默病的有效生物标志物:系统评价和荟萃分析。
Biomolecules. 2021 Jul 3;11(7):980. doi: 10.3390/biom11070980.
5
Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer's Disease.线粒体功能障碍作为阿尔茨海默病认知障碍的驱动因素。
Int J Mol Sci. 2021 May 3;22(9):4850. doi: 10.3390/ijms22094850.
6
Alzheimer disease.阿尔茨海默病。
Nat Rev Dis Primers. 2021 May 13;7(1):33. doi: 10.1038/s41572-021-00269-y.
7
Effects of different aerobic exercise training on glycemia in patients with type 2 diabetes: A protocol for systematic review and meta analysis.不同有氧运动训练对 2 型糖尿病患者血糖的影响:系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 May 7;100(18):e25615. doi: 10.1097/MD.0000000000025615.
8
Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges.基于纳米医学的技术和新型生物标志物在阿尔茨海默病诊断和治疗中的应用:从当前到未来的挑战。
J Nanobiotechnology. 2021 Apr 29;19(1):122. doi: 10.1186/s12951-021-00864-x.
9
Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead.神经退行性疾病中的遗传和转录组生物标志物:现状与未来展望。
Cells. 2021 Apr 27;10(5):1030. doi: 10.3390/cells10051030.
10
Mechanistic insights into the pathogenesis of neurodegenerative diseases: towards the development of effective therapy.神经退行性疾病发病机制的研究进展:寻找有效的治疗方法。
Mol Cell Biochem. 2021 Jul;476(7):2739-2752. doi: 10.1007/s11010-021-04120-6. Epub 2021 Mar 9.